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Abstract 
Background: Cisplatin (DDP)-based chemotherapy is the mainstay of first-line therapy for lung cancer. However, 
their efficacy is often limited by the existence or development of chemoresistance. The aim of this study was to find 
and investigate the function of miRNAs in cisplatin (DDP)-resistant non-small cell lung cancer (NSCLC) A549 cell.
Methods: Quantitative real-time PCR assay was employed to compare the differences of miRNA expression in both 
cisplatin-resistant A549 (A549/DDP) cell and the parental A549 cell. The dysregulated miRNAs were then corrected 
by transfecting oligonucleotides into A549/DDP cells. The cellular sensitivity to cisplatin, cell apoptosis and migration 
were conducted by MTT, flow cytometry and cell wound healing assay, respectively.
Results: Both miR-589 and miR-1244 were significantly down-regulated in A549/DDP cell compared to the parental 
A549, while the expression of miR-182 and miR-224 were increased in A549/DDP cell (P < 0.05). Importantly, transfec-
tion of the cisplatin-resistant cells with either miR-589 or miR-1244 resulted in an increased sensitivity to cisplatin, 
indicating that the dysregulated miRNA may play an important role in chemotherapy resistance in cancer cell. The 
rescued expression of miRNA also reduced cell invasion and increased apoptosis of A549/DDP cell.
Conclusion: The study indicates a crucial role of miR-1244 in the progress of cisplatin resistance of A549. Further 
understanding of miR-1244-mediated signaling pathways may promote the clinical use of miR-1244 in lung cancer 
therapy.
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Background
Lung cancer is one of the most common malignancy 
worldwide [1]. Almost 85 % of lung cancer cases belong 
to non-small-cell lung cancer (NSCLC) [2]. Currently, 
chemotherapeutic agents are widely used in the treat-
ment of lung cancer. Cisplatin (DDP), a platinum-based 
compound, is one of the first-line chemotherapeutic 
agents for the treatment of NSCLC [3, 4]. However, its 
efficacy is often limited by the development of chemore-
sistance [5, 6]. Therefore, study of the molecular mecha-
nisms of DDP resistance will aid the clinician to oversee 
the resistance in advance thus improving the efficacy of 
lung cancer therapeutics.
microRNAs is a family of small, non-coding RNAs 
which function as a novel class of gene expression regu-
lators at posttranscriptional level [7–9], thus resulting 
in mRNA destabilization and translational repression 
[9–11], a process involved in the regulation of cellular 
development, proliferation, differentiation, apoptosis 
and metabolism [9, 12–14]. Significant amount of stud-
ies showed dysregulations of miRNAs are associated 
with the initiation and progression of cancers [15, 16]. 
Different expression levels of miRNA were found in vari-
ous human cancers including NSCLC [16]. Recently, the 
miRNA expression was observed to be linked with tumor 
response to chemotherapies, including cisplatin [17, 18].
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In order to study the molecular mechanisms of miR-
NAs for the acquired DDP resistance of lung cancer 
cells, we firstly established a DDP-resistant lung can-
cer cell (A549/DDP) from the parental A549, a cisplatin 
sensitive line. We found that miR-589 and miR-1244 
were significantly down-regulated in the A549/DDP cell 
line. This is interesting, as there has no published data 
on the roles of miR-589 and/or miR-1244 in the devel-
opment of DDP-resistance of lung cancer cells. There-
fore, we hypothesized that miR-589 or miR-1244 may 




The parental lung cancer A549 cell was purchased from 
Shanghai Institute of Cell Biology (Shanghai, China). 
The DDP-resistant cell line (A549/DDP) was established 
as previously published [19]. Briefly, DDP was added 
into A549 cells in the log phase at a concentration of 
0.2  μg/ml and remained in the medium. After growth, 
the cells were split and treated again with progressively 
higher concentrations of DDP. During the treatment, 
the DDP concentration was increased to 15  μg/ml. All 
cell lines were cultured in Dulbecco’s modified Eagles 
medium (DMEM) containing 10  % fetal bovine serum 
(Gibco, NY, USA) in the humidified air with 5 % CO2 at 
37 °C.
Transfection of microRNA mimics or inhibitors
Cells seeded in a 6-well plate (2.5 ×  105 per well) were 
transfected at 50  % confluence using Lipofectamine 
RNAiMAX Transfection Reagent (Invitrogen, CA, USA) 
with Opti-MEMI (Gibco, NY, USA) according to the 
manufacturer’s instructions. After 24 or 48 h, the trans-
fected cells were harvested for downstream analyses or 
measured for cell wound healing assay. Both of micro-
RNA mimics, inhibitors and their negative control were 
purchased from Invitrogen (Invitrogen, CA, USA).
Quantitative real‑time PCR (qRT‑PCR) assays
Total RNA was isolated using TRIzol reagent (Invitro-
gen, CA, USA) according to the manufacturer’s instruc-
tions, and A260/280 and A260/230 ratios were measured 
using the Nanodrop 2000 (Thermo Scientific, PA, USA). 
Approximately 500  ng of total RNA was converted to 
cDNA by First-strand cDNA synthesis kit (OriGene 
Technologies, MD, USA). Quantitative real-time PCR 
was then conducted using SYBR® Green mastermix 
(cwbio, China) in a 7500 Fast PCR instrument (Applied 
Biosystems, CA, USA). All samples were run in triplicate 
in the 96-well reaction plates.
MTT assay
The cells (2 × 103) in the log growth phase were seeded 
in a 96–well plate. After overnight growth, the cells were 
transfected by oligonucleotides (Invitrogen, CA, USA) 
as described above. After 24  h of transfection, the cells 
were treated with different dose of cisplatin (0, 20, 40, 
80, 160 µg/ml) and incubated for 48 h. A total of 20 μl of 
5  mg/ml MTT reagent (Sigma-Aldrich, MO, USA) was 
added and incubated in the incubator for 4 h. The plate 
was then read in a microplate reader at a wavelength of a 
490 nm reference.
Cell wound healing assay
The cells were seeded in a 6-well plate (1 × 106 per well). 
After confluent, a linear wound was made using a 10 μl 
pipette tip across the cell monolayer. The cells were 
grown in DMEM supplemented with 3  % FBS for addi-
tional 48  h. The cell motility was measured by photo-
graphing five random areas at the time of 0, 24 and 48 h 
after wounding.
Analysis of apoptosis by flow cytometry
The annexin V-FITC Apoptosis Detection Kit (Multi-
Sciences Biotech Co, China) was used to quantify apop-
tosis by flow cytometry. The cells were harvested in PBS 
and collected by centrifugation. The cells were then re-
suspended in the binding buffer, stained with FITC and 
PI for 5 min and immediately analyzed by flow cytometer.
Western blot assay
The cells were harvested and lysed in RIPA buffer in the 
presence of protease inhibitors (Roche, Mannheim, Ger-
many) for 10  min at 4  °C. Protein concentration in the 
supernatants was quantified using the Bio-Rad Protein 
Assay Kit (Bio-Rad Laboratories, CA, USA). Proteins 
(30  μg) were separated by 15  % SDS-PAGE and then 
transferred to PVDF membranes (Millipore, Bedford, 
MA). After blocking with 5  % nonfat milk in TBST for 
1 h, the blot was incubated with the primary antibodies 
overnight at 4  °C. After three washes (15  min each) in 
TBST, blots were incubated with horseradish peroxidase-
conjugated secondary antibodies and developed using 
an ECL detection system. All images showed were from 
a single experiment that was a representative of at least 
three independent replicate experiments.
Bioinformatics and statistical analysis
MiRNA target analysis was conducted by miRDB (http://
www.mirdb.org/miRDB/), Targetscan (http://www.tar-
getscan.org/) and CLIP-Seq. All data were presented as 
the mean  ±  SD of three or more replications, and the 
Student’s t test was used to test the significance between 
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two groups. Data analysis was performed using Graph-
Pad Prism 4.0 (Graph Pad Software, La Jolla, CA) and 
two-tailed P < 0.05 were considered to be significant.
Results
The different expression of miRNA between A549 
and A549/DDP cells
Previously, we have identified by array analysis a set of 
miRNAs differentially expressed in NSCLC tissues com-
pared to healthy controls (manuscript under review). 
In this study, we employed qRT-PCR assay to assess the 
expression level of the miRNAs in both A549 and A549/
DDP cells. Among 37 miRNAs, we observed that 11 miR-
NAs were upregulated and other 26 miRNAs were down-
regulated in A549/DDP cell line (Fig.  1a). Especially, 
miR-589 and miR-1244 were significantly decreased in 
A549/DDP cell (Fig.  1b), while miR-182 and miR-224 
were increased in A549/DDP cell (Fig. 1c).
Transfection with miR‑mimics or miR‑inhibitors
MiRNA mimic is a short sequence of oligonucleotides 
synthesized by chemical method which can enhance the 
functions of endogenous miRNA, while miRNA inhibi-
tor is a modified oligonucleotide that can incorporate 
into the target miRNA thus attenuating its function. To 
further assess the effects of the dysregulated miRNA on 
DDP resistance of A549/DDP cell, we transfected the 
miRNA mimic for miR-589 or miR-1244, and the miRNA 
inhibitor for miR-182 or miR-224 into A549/DDP cells. 
As shown in Fig. 1c, the relative expression levels of miR-
589 and miR-1244 are significantly increased in A549/
DDP transfected by mimic miRNAs compared to the 
negative controls (Fig. 1d). Likewise, the expression level 
of miR-182 and miR-224 are significantly decreased in 
A549/DDP cell after transfection of miRNA inhibitors 
(Fig.  1e), indicating both mimic and inhibitory oligonu-
cleotides could revert, at least in partial, the expression 
level of its corresponding miRNA.
The miRNA mimic sensitizes A549/DDP cells to DDP
We hypothesized that the corrected miRNA expression 
might sensitize A549/DDP cells to DDP.  To this end, 
we first transfected A549/DDP cells by either miR-589 
mimic or miR-1244 mimic followed by the treatment 
with various doses of DDP (0, 20, 40, 80 and 160 μg/ml) 
for 48  h. The MTT assay showed that up-regulation of 
miR-589 or miR-1244 led to a significant decrease in cell 
viability of A549/DDP in response to DDP compared to 
A549/DDP-NC (Fig. 2a). The IC50 value for DDP in both 
A549/DDP-miR-1244 (5.66  ±  2.32  μg/ml) and A549/
DDP-miR-589 cell (6.53 ± 2.21 μg/ml) were significantly 
lower that of A549/DDP-miR-NC cell (30.1  ±  3.44  μg/
ml) (P  <  0.05). However, reduction of miR-182 or 
miR-224 has no effects on the sensitivity of A549/DDP 
to DDP (Fig. 2b). The IC50 in A549/DDP-anti miR-224, 
A549/DDP-anti miR-182 and A549/DDP-anti miR-NC 
cells were 83.76 ± 5.03, 28.77 ± 4.09 and 23.7 ± 2.47 μg/
ml, respectively. These data suggested that up-regulation 
of miR-589 or miR-1244 effectively enhances the sensitiv-
ity of A549/DDP cells to DDP.
Over‑expression of miR‑589 or miR‑1244 induces cell 
apoptosis
We next analyzed the effect of miR-589 or miR-1244 
by flow cytometry on apoptosis of A549/DDP cell after 
introduction of miR-589 or miR-1244. The apoptotic 
cells were increased in A549/DDP cell transfected with 
miR-589 or miR-1244 mimics, but not miR-NC (Fig. 3a), 
suggesting either miR-589 or miR-1244 could induce the 
apoptosis of non-small cell lung cancer cells. As showed 
in Fig.  3b, the apoptosis rates of A549/DDP cells trans-
fected with miR-1244 mimic, miR-589 mimic and control 
were 28.83 %, 38.78 versus 10.5 % (P < 0.05).
To further verify the miR-589 or miR-1244-induced 
cell apoptosis, we examined activation of the caspase-3, 
a hallmark of apoptosis. As showed by western blot 
(Fig. 3c), there is a significant band for cleaved caspase-3 
in miR-589-transfected cells in comparison to the nega-
tive control at 24 h, indicating early events in the apopto-
sis pathway.
miR‑589 or miR‑1244 reduces A549/DDP cell migration
To evaluate the impact of miR-589 or miR-1244 on the 
migration of the DDP-resistant cells, we performed cell 
wound healing assay. Interestingly, the migration rate 
of the transfected cells by either miR-589 or miR-1244 
mimics was significantly reduced compared to miR-NC 
at both 24 h and 48 h (Fig. 3d, e), indicated that miR-589 
or miR-1244 inhibits the cell mobility of A549/DDP cells.
Molecular targets of miR‑1244
To gain insight into the possible molecular mechanisms 
underlying the striking difference in the expression of 
miRNA, especially miR-1244, between A549/DDP and 
A549 cells, we predicted the potential target of miR-1244 
using miRDB (http://www.mirdb.org/miRDB/), Targets-
can (http://www.targetscan.org/) and CLIP-Seq. Among 
hundreds of the target genes predicted, we selected the 
most likely target genes and validated their expressions 
by qPCR. Importantly, 13 out of 17 top genes were con-
firmed up-regulated in the A549/DDP cells transfected 
by miR-1244, while 4 target genes were confirmed down-
regulated, particularly NEDD4 (Fig. 4a). As an E3 ligase, 
knockdown of NEDD4 was showed to increase basal 
TP53 levels, thus causing stronger TP53 responses to 
DNA damage [20], we therefore analyzed the expression 
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level of TP53 by QPCR. Interestingly, TP53 was found 
over-expression in the A549/DDP upon transfection 
of miR-1244 (Fig.  4b), indicating TP53 is one of the 
potential targets of miR-1244. This observation was 
further confirmed at protein level by western blot. As 
showed in Fig. 4c, while NEDD4 was down-regulated, the 


















































Fig. 1 Quantitative real-time PCR analysis of the expression of microRNAs in A549 cells and A549/DDP cells. a The relative expressions of 37 miRNAs 
in A549/DDP cells. The data were normalized by their expression in A549 cells. b, cThe expression levels of miR-1244, miR-589, miR-224 and miR-
182. The results are the average of triplicate experiments. d, e Fold changes of miR-1244, miR-589, miR-224 or miR-182 in A549/DDP cells after 48 h 
of transfection with the mimics or inhibitors, respectively. The results are the average of triplicate experiments. **P < 0.05
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translational product of TP53 was significantly induced 
in A549/DDP-miR-1244 compared to A549/DDP-miR-
NC cell. These data imply p53 protein might be involved 
in the process of chemoresistance of tumor cells.
Discussion
Despite the great advances in cancer therapy, chemo-
resistance is still the daunting challenge for the treat-
ment of advanced lung cancer. Accumulating studies 
suggest that miRNAs might be one of the molecular 
mechanisms of multidrug resistance in human cancers 
[21, 22]. For example, up-regulation of miR-451, miR-98 
and miR-513a-3p increased cisplatin sensitivity in human 
lung adenocarcinoma cells [17, 18, 23], while miR-495 
enhanced the sensitivity of NSCLC cells to platinum [24]. 
These studies highlighted the important role of miRNAs 
in regulating lung cancer DDP-resistance.
In this study, we observed that miR-1244 and miR-589 
were significantly down-regulated in A549/DDP cell, 
while miR-224 and miR-182 were markedly up-regulated 
in A549/DDP cell. The corrected expression of miR-1244 
and miR-589 increased the sensitivity of A549/DDP cells 
to cisplatin, and induced cell apoptosis. These results 
indicated that both miR-1244 and miR-589 play an 
important role in the development of cisplatin resistance 
in NSCLC.
To our best knowledge, this is the first study showing 
that miR-1244 was down-regulated upon acquisition of 
drug-resistance to cisplatin in A549 cell. MiR-1244 acts 
as a tumor suppressor in lung cancer by reducing its pro-
liferation, survival and invasion, and its under-expression 
is highly associated with patients’ survival [25]. This 
could explain our observation that the rescued expres-
sion of miR-1244 could sensitize A549/DDP cells to 
DDP via inhibiting cell migration and/or increasing cell 
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Fig. 2 Sensitivity of A549/DDP to cisplatin by MTT assay. a Overex-
pression of miR-589 or miR-1244 attenuates the sensitivity of A549/
DDP cells in response to DDP compared to A549/miR-NC cells. 
b Down-regulation of miR-182 or miR-224 has no effects on the 
sensitivity of A549/DDP cells to DDP. Each treatment was carried out 
in quadruplicate























































































































Fig. 3 Effects of miR-1244 or miR-589 on cell apoptosis and migration in A549/DDP cells. a, b Flow cytometry analysis of apoptosis in A549/DDP-
miR-1244 cells (left) or A549/DDP-miR-589 cells (middle) compared to A549/DDP-miR-NC cells (right). c Western blot analysis of caspase-3 expression 
in response to either miR-589 or miR-1244 transfection in A549/DDP cells. GAPDH was used as internal control. d The wound healing assay was 
performed on A549/DDP cell transfected by miR-589 or miR-1244. e Migration rate of each group. All experiments were performed in triplicate, and 
a representative image is shown (**P < 0.05)
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apoptosis, likely explaining the mechanism of miR-1244 
in chemo-resistance of NSCLC.
Interestingly, miR-589 has been reported to repress 
epithelial-mesenchymal transition (EMT) in human 
peritoneal mesothelial cells [23]. While EMT is a critical 
event initiating cancer invasion and metastasis, and dys-
regulation of EMT could increases the drug-resistance 
to many therapeutic agents [26], thus perfect in line with 
our findings that overexpression of miR-589 sensitizes 
A549/DDP cells to cisplatin.
TP53 is a tumor suppressor gene and it is frequently 
mutated in a variety of human cancers including lung 
cancer, thus contributing to the acquisition and/or main-
tenance of drug resistance of malignant cancers. Our 
results showed over-expression of miR1244 in A549/DDP 
indirectly induced the expression of TP53 at both gene 
and protein levels. Therefore, down-regulated miR1244 
in A549/DDP cell might contribute to the development 
of cisplatin-resistance via prohibiting TP53 regulated 
cell signaling pathway. These data underline the impor-
tance of miR-1244 in regulating the cisplatin resistance of 
NSCLC, and render a new angle toward target therapy of 
chemoresistance for cancer patients.
Conclusion
The study indicates a crucial role of miR-1244 in regu-
lating the cisplatin resistance of NSCLC. Further under-
standing of miR-1244-mediated signaling pathways may 
render a new angle toward target therapy of chemoresist-
ance for cancer patients.
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